Jane Street
BCAX

Jane Street’s Bicara Therapeutics BCAX Stock Holding History

Jane Street’s Portfolio BCAX Stock Details BCAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-85,583
Closed -$1.47M – 13306
2025
Q4 		$1.44M Buy
+85,583
New +$1.46M ﹤0.01% 5400
2025
Q3 		– Sell
-28,604
Closed -$266K – 12044
2025
Q2 		$266K Buy
+28,604
New +$341K ﹤0.01% 8067
2024
Q4 		– Sell
-12,151
Closed -$309K – 10856
2024
Q3 		$309K Buy
+12,151
New +$310K ﹤0.01% 7976

Other funds holding BCAX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
RTM
Red Tree Management Redwood City, California $147M AUM 202.18% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Jane Street's BCAX Position: Q1 2026 in Review

Jane Street sold out of Bicara Therapeutics (BCAX) in Q1 2026, closing a stake of 85,583 shares — an estimated $1.47M sold.

Jane Street first reported a position in BCAX in Q3 2024 and held it in 3 quarters. The position peaked at $1.44M in Q4 2025. 146 funds tracked by Wall St. Rank hold BCAX as of Q1 2026.

  • Jane Street reported no remaining Bicara Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Jane Street sold 85,583 Bicara Therapeutics shares in Q1 2026, an estimated $1.47M.
  • Jane Street first reported a position in Bicara Therapeutics in Q3 2024 and held it in 3 quarters.
  • Jane Street's Bicara Therapeutics position peaked at $1.44M in Q4 2025.
  • 146 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q1 2026.

Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.